CTOs on the Move

64x Bio

www.64xbio.com

 
64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.64xbio.com
  • 409 Illinois Street
    San Francisco, CA USA 94158
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Tolerx

Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people`s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world`s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Avalyn Pharma

Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.

Bioriginal Food and Science

Bioriginal Food and Science Corp. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Totient

Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics.